Swiss dental implant makers are expected to report another round of weak earnings in their upcoming quarterly reports, according to story on cnnmoney.com.
Analysts say that Biomet 3i's fourth-quarter results, announced June 26, indicate that "the dental implant market remains in a depressed mode due to the difficult economic environment and the discretionary nature of dental implant procedures," cnnmoney.com reported.
While Biomet saw its year-over-year revenues grow slightly, to $639.3 million from $635.6 million in the same quarter a year ago, the company's dental reconstructive device sales fell 19% worldwide, with a 15% decrease in the U.S., according to a Biomet press release. However, fourth-quarter dental reconstructive sales increased slightly compared to third-quarter sales, indicating a potential sign of stabilization, Biomet said in the release.
Some analysts expect Nobel Biocare to post a 6.3% decline in second-quarter sales, while Straumann should see sales fall by 2.3%, while others estimate a 12% decline for Nobel and 5% for Straumann, according to cnnmoney.com.
Copyright © 2009 DrBicuspid.com
.RbyOLNR6ps.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
.RbyOLNR6ps.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
